Biotechnology

Sino Biological

Sino Biological released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 183.42 M, actual EPS CNY 0.2643

Sino Biological to Release FY2026 Q1 Earnings Report on April 29 After-Market BJT

Sino Biological released FY2025 Q4 earnings on April 13 After-Market (BJT), actual revenue CNY 188.12 M, actual EPS CNY 0.3088

Sino Biological released FY2025 earnings on April 13 After-Market (BJT), actual revenue CNY 699.56 M (forecast CNY 651 M), actual EPS CNY 1.2146 (forecast CNY 1.19)

Sino Biological to Release FY2025 Earnings on April 14 After-Market (BJT), Forecast Revenue CNY 651 M, EPS CNY 1.19

Sino Biological released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 186.99 M, actual EPS CNY 0.3492

Sino Biological released FY2025 9 Months Earnings on October 27 After-Market BJT, actual revenue CNY 511.45 M, actual EPS CNY 0.9057

Sino Biological to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

Sino Biological released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), actual revenue CNY 324.46 M, actual EPS CNY 0.5565

Sino Biological released FY2025 Q2 earnings on August 26 After-Market BJT, actual revenue CNY 169.15 M, actual EPS CNY 0.3704

Sino Biological to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Yisao 神州 and Guangdong Provincial Institute of Public Health Establish Joint Lab

Sino Biological released FY2025 Q1 earnings on April 23 Pre-Market (BJT), actual revenue CNY 155.3 M, actual EPS CNY 0.1861

Yishao Shenzhou's Net Profit Decreased by 53.13% in 2024

Sino Biological released FY2024 annual earnings on April 18 After-Market BJT, actual revenue CNY 613.67 M (forecast CNY 626 M), actual EPS CNY 0.953 (forecast CNY 1.28)

Sino Biological released FY2024 Q4 earnings on April 18 After-Market BJT, actual revenue CNY 148.72 M, actual EPS CNY 0.175

Sino Biological to Release FY2025 Q1 Earnings on April 24 Pre-Market BJT

Sino Biological to Release FY2024 Annual Earnings on April 19 After-Market BJT, Forecast Revenue CNY 626 M, EPS CNY 1.28

Yiqiao Shenzhou announced the cumulative repurchase of shares

Sino Biological, Inc. to Announce Q3 2024 Earnings on October 23, 2024

301047

Sino Biological has introduced ProPure™ endotoxin-free proteins, achieving levels below 0.05 EU/mg, significantly surpassing the industry standard of 0.5 EU/mg. These proteins are crucial for ensuring experimental accuracy and safety in research, particularly in immunology, cell/gene therapy, and vaccine production. The ultra-low endotoxin levels help prevent skewed results and enhance data reliability, addressing challenges posed by endotoxin contamination in scientific studies. Sino Biological's advanced technology and rigorous quality control ensure the highest standards for researchers.

prnewswire

03:22 ETThe 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

Sino Biological has launched antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains in response to WHO's recommendations. The new strains include A/Darwin/1454/2025 for H3N2 and B/Tokyo/EIS13-175/2025 for B/Victoria lineage, as the H3N2 subclade K strain shows enhanced immune escape. Sino Biological aims to support global vaccine research with high-quality recombinant antigens, emphasizing its commitment to public health preparedness.

20:53 ETAdvancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

Sino Biological, Inc. has launched its innovative SwiftFluo® TR-FRET kinase assay kits, designed for high-performance detection of kinase inhibitors. Utilizing advanced time-resolved fluorescence resonance energy transfer (TR-FRET) technology, these kits provide exceptional sensitivity and robust reproducibility, enabling rapid and scalable screening of kinase inhibitors. Optimized for profiling over 60 tyrosine kinases, 150 serine/threonine kinases, and 15 cyclin-dependent kinases, they offer significant advantages over traditional methods. The kits facilitate homogeneous assays without washing, compatible with standard HTS platforms, thus streamlining workflows for researchers.

11:15 ET
			
			
			
				
					El lanzamiento de los kits SwiftFluo® TR-FRET de Sino Biological marca una nueva era

According to the Zhitong Finance APP, Sino Biological released its third-quarter report for 2025. The company's operating income for the first three quarters was 511 million yuan, a year-on-year increase of 10.00%. The net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 10.94%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 62.2531 million yuan, a year-on-year increase of 75.30%. The basic earnings per share were 0.9058 yuan

Zhitong

Sino Biological released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, an increase of 10.94%

Sino Biological announced that the company's controlling shareholder, Lhasa Ailike Investment Consulting Co., Ltd., pledged 4.5 million shares of the company on September 4, 2025, accounting for 6.91% of its holdings and 3.70% of the company's total share capital. The pledge start date is September 4, 2025, and the purpose of the pledge is for financing. The pledged shares do not have significant asset restructuring or performance compensation obligations

Sino Biological: The controlling shareholder Aileke pledged 3.70% of the company's shares

Sino Biological(301047.SZ)

03:22 ETThe 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

20:53 ETAdvancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

11:15 ET El lanzamiento de los kits SwiftFluo® TR-FRET de Sino Biological marca una nueva era

Sino Biological released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, an increase of 10.94%

Sino Biological: The controlling shareholder Aileke pledged 3.70% of the company's shares